Regeneron's Profit Soared 31% on Higher Collaboration Revenue and Eylea Sales

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Shareholders of Regeneron Pharmaceuticals (NASDAQ: REGN  ) can certainly see a little clearer now after their company once again delivered impressive growth in the first quarter on the heels of its blockbuster ophthalmic drug, Eylea.

For the quarter, total revenue soared 42% to $626 million from $440 million in the year-ago period. Net product sales of wet aged-related macular degeneration drug Eylea jumped 14% to $359 million in the U.S., but were negatively affected by a decrease in distributor inventory. Sans this impact, Eylea demand improved by 25% year over year. Outside the U.S., net sales of Eylea shot up to $218 million, of which Regeneron, in collaboration with marketing partner Bayer (NASDAQOTH: BAYRY  ) , which is responsible for commercializing Eylea in all ex-U.S. markets, received $61 million for its share of net profit.

Also boosting revenue was a 125% surge in collaborative revenue to $256 million due to the commercialization of Eylea in ex-U.S. countries, and higher research and development reimbursement from its collaboration with Sanofi.

In line with its growing pipeline, R&D and selling, general and administrative expenses rose by 59% and 41%, respectively, from the prior year period.

Profit for the period motored higher by 31% to $263 million, or $2.26 on an adjusted EPS basis, compared to $201 million, or $1.78 in EPS in the year-ago quarter. Regeneron also announced that its cash and marketable securities position improved to $1.18 billion from $1.08 billion in the sequential fourth quarter.

Looking ahead, Regeneron reiterated its previous forecast which calls for $1.7 billion-$1.8 billion in net sales for Eylea.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2949509, ~/Articles/ArticleHandler.aspx, 8/31/2015 6:04:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 4:00 PM
REGN $513.50 Down -23.20 -4.32%
Regeneron Pharmace… CAPS Rating: ***
BAYRY $135.60 Down -0.43 -0.31%
Bayer AG (ADR) CAPS Rating: ****